Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Annette Jappe"'
Publikováno v:
The Journal of Clinical Pharmacology. 53:444-450
The selective mammalian target of rapamycin (mTOR) inhibitor everolimus has demonstrated competitive inhibition of cytochrome P450 enzyme (CYP) 3A4 in vitro; however, its influence on CYP3A4 activity in humans is unknown. This study examined the infl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a738917bda822d5cff3df20d81d6bb7
https://doi.org/10.1002/jcph.7
https://doi.org/10.1002/jcph.7
Autor:
Bruce E. Johnson, Valentine Jehl, Jean-Charles Soria, Vassiliki A. Papadimitrakopoulou, Judith Klimovsky, Annette Jappe
Publikováno v:
Journal of Thoracic Oncology. 7:1594-1601
Introduction The epidermal growth factor receptor inhibitor erlotinib is an approved treatment for chemotherapy-refractory advanced non–small-cell lung cancer (NSCLC). Because activated epidermal growth factor receptor signals through the phosphati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b94f4323f95e413763e7cc351a5a050
https://doi.org/10.1097/jto.0b013e3182614835
https://doi.org/10.1097/jto.0b013e3182614835
Autor:
Gentil Alves Filho, Vincenzo Cambi, Giovanni Civati, Scott B. Campbell, Stefan Vitko, Tomas Haas, Paolo Rigotti, Nathalie Cretin, Bernard Bourbigot, John C. Magee, Josette Eris, H. Tedesco, Ronaldo de Matos Esmeraldo, Annette Jappe, Peter Bernhardt, John Leone, Julio Pascual, Valter Duro Garcia, J. Whelchel, Johanna Geissler
Publikováno v:
American Journal of Transplantation. 4:626-635
Two prospective, randomized studies evaluated everolimus 1.5 vs. 3 mg/day with steroids and low-exposure cyclosporine (CsA) (C2 monitoring) in de novo renal transplant patients. Everolimus dosing was adjusted to maintain a minimum trough level of 3 n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7800c3311641eb96dba9a08c6e2f33d0
https://doi.org/10.1111/j.1600-6143.2004.00389.x
https://doi.org/10.1111/j.1600-6143.2004.00389.x
Autor:
Nathalie Cretin, Annette Jappe, Stefan Vitko, Yulan Li, Hendrik G. Viljoen, Jacques Dantal, Raimund Margreiter, Willem Weimar
Publikováno v:
Transplantation, 78(10), 1532-1540. Lippincott Williams & Wilkins
Background Everolimus is a proliferation inhibitor designed to target chronic rejection, including prevention of acute rejection. Everolimus blocks growth factor-mediated transduction signals, preventing organ rejection by a mechanism different than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::963731e49a03017a3f7698043bb166f8
https://hdl.handle.net/1765/65839
https://hdl.handle.net/1765/65839
Autor:
RuiRong Yuan, Yi-Long Wu, DingWei Ye, Lin Shen, Azzeddine Cherfi, Annette Jappe, Hui Wang, Binghe Xu
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 4, Iss 1, p 3 (2011)
Journal of Hematology & Oncology, Vol 4, Iss 1, p 3 (2011)
Background This phase I, randomized, multicenter, open-label study investigated the pharmacokinetics, safety, and efficacy of the oral mammalian target of rapamycin inhibitor everolimus in Chinese patients with advanced solid tumors. Methods A total
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b7e65ef47a9173e9ce414b4b102f990
https://doi.org/10.1186/1756-8722-4-3
https://doi.org/10.1186/1756-8722-4-3
Autor:
Annette Jappe, Ho Yeong Lim, Jean-Frédéric Blanc, Kevin Perraud, Dalila Sellami, Ronnie T.P. Poon, Arndt Vogel, Yoon-Koo Kang, Junji Furuse, Masatoshi Kudo, Eric Assenat, Etienne Dorval, Markus Peck-Radosavljevic, Stéphane Cattan, Andrew X. Zhu, Bruno Daniele, Armando Santoro, Oezlem Anak, Li-Tzong Chen, Chao-Long Chen
Publikováno v:
JAMA. 312:57
Aside from the multikinase inhibitor sorafenib, there are no effective systemic therapies for the treatment of advanced hepatocellular carcinoma.To assess the efficacy of everolimus in patients with advanced hepatocellular carcinoma for whom sorafeni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e7280a1ecaefb97fc0789c2550211cf
https://doi.org/10.1001/jama.2014.7189
https://doi.org/10.1001/jama.2014.7189
Autor:
Jean-Frédéric Blanc, Eric Assenat, Andrew X. Zhu, Li-Tzong Chen, Bruno Daniele, Ho Yeong Lim, Annette Jappe, Chao-Long Chen, Etienne Dorval, Dalila Sellami, Kevin Perraud, Junji Furuse, Arndt Vogel, Markus Peck-Radosavljevic, Stéphane Cattan, Yoon-Koo Kang, Özlem Anak, Ronnie T.P. Poon, Masatoshi Kudo, Armando Santoro
Publikováno v:
Journal of Clinical Oncology. 32:172-172
172 Background: No effective treatment options exist for advanced HCC following sorafenib failure. Preliminary data suggest everolimus may provide benefit after sorafenib. EVOLVE-1 (NCT01035229) assessed the efficacy and safety of everolimus for adva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3fd3a119527e4017b0e849f92be1d0d8
https://doi.org/10.1200/jco.2014.32.3_suppl.172
https://doi.org/10.1200/jco.2014.32.3_suppl.172
Autor:
Judith Klimovsky, Valentine Jehl, Vassiliki A. Papadimitrakopoulou, Normand Blais, J-C. Soria, Jaafar Bennouna, Natasha B. Leighl, Bruce E. Johnson, A. M. Traynor, Annette Jappe
Publikováno v:
Journal of Clinical Oncology. 28:7524-7524
7524 Background: Everolimus (RAD001) is an oral mTOR inhibitor that has been evaluated as monotherapy in a phase II study of NSCLC patients (pts) previously treated with platinum-based chemotherapy...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::667e7357794b7f5f800ab168932fd34b
https://doi.org/10.1200/jco.2010.28.15_suppl.7524
https://doi.org/10.1200/jco.2010.28.15_suppl.7524
Publikováno v:
Journal of Clinical Oncology. 28:e13094-e13094
e13094 Background: The mammalian target of rapamycin (mTOR), a regulator of cell growth, proliferation, and angiogenesis, is commonly dysregulated in cancer. This phase I, randomized, multicenter, ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::985c5aceb48692fbf894bc0d59760ad8
https://doi.org/10.1200/jco.2010.28.15_suppl.e13094
https://doi.org/10.1200/jco.2010.28.15_suppl.e13094
Autor:
tefan Vtko, Raimund Margreiter, Willem Weimar, Jacques Dantal, Hendrik G Viljoen, Yulan Li, Annette Jappe, Nathalie Cretin
Publikováno v:
Transplantation; Nov2004, Vol. 78 Issue 10, p1532-1540, 9p